The treatment of CD133+ CR-CSCs with BMP4 induces in vitro differentiation and reduces their tumorigenic potential; moreover in vivo the combined treatment with BMP4 and conventional chemotherapeutics reduces the tumor size [98]. The gene discussed is BMP4; the disease is neoplasm.